Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Covidien Agrees To Buy Israeli Medical Device Maker

RELATED NEWS
Trade COV now with 

U.S. medical device maker Covidien (COV: Quote) has reached a definitive agreement to acquire Super-Dimension, the Israeli manufacturer of pulmonary devices. The purchase price for the deal is nearly $300 million, with some future payments possible, contingent on the performance of the company.

Super-Dimension's i·main product is its Logic System, which uses Electromagnetic Navigation Bronchoscopy. This high-tech method of navigation allows health professionals access to lesions deep in the lungs as well as in mediastinal lymph nodes.

The acquisition may close in the second calendar quarter of 2012.

Assuming a second calendar quarter 2012 closing, Covidien does not anticipate this transaction to have a material impact on its fiscal 2012 sales. Upon the close of the transation, Covidien would report the superDimension business in the Endomechanical product line within the Medical Devices segment.

Click here to receive FREE breaking news email alerts for Covidien Plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.